clinical trial · NCT07228559
A Study of Avoralstat In Participants With Diabetic Macular Edema
Diabetic Macular Edema (DME)avoralstat
brief summary
The goal of this study is to assess the safety and therapeutic potential of a single dose of avoralstat in adult participants with DME.
started
Oct 2, 2025
primary completion
May 1, 2026
completion
Sep 1, 2026
last updated
Apr 7, 2026
detailed description
Study BCX4161-111 is an open-label, single ascending dose study with 24 weeks follow-up in participants with DME. Three cohorts with a minimum of 3 participants enrolled in each cohort with 3 dose levels of avoralstat (low, medium, high) are planned.
official title
A Phase 1b Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Suprachoroidal Injection of Avoralstat In Participants With Diabetic Macular Edema
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol